

September 2026

Investment Objective: The investment objective of the Fund is to generate long-term returns through investment in a portfolio of global companies whose share prices stand at a significant discount to estimated underlying net asset value.

HEADLINES

Introduction

In September, the fund returned -2.5%.

[Read more below](#)

Christian Dior

The Arnault family intends to launch a cash offer for the 2.4% of CDI they don't own.

[Read more below](#)

Bio-Rad Labs

We introduce a new position – which has performed well to date but we believe has much more to come.

[Read more below](#)

THE FUND

Fund Launch Date

17/04/24

A GBP NAV per share

£107.14


Cash

3.0%

Net Performance (GBP)

Total Returns (%)	Month	3 Month	YTD	SI ¹
A GBP Share Class	-2.5	5.8	7.2	7.1
MSCI ACWI	0.9	1.5	14.4	47.1
IA Global	-0.6	0.4	10.4	31.9

NAV Total Return Since Inception (GBP)



Past performance does not predict future returns. All performance is shown in GBP, net of fees and including net dividends as at 30/09/2026. Returns may increase or decrease as a result of currency fluctuations. Source: Morningstar. Benchmark: MSCI® All Country World Net Total Return Index. The Fund is actively managed with reference to the MSCI® All Country World Net Total Return Index for performance comparison purposes. The portfolio is unconstrained by the benchmark and holdings may deviate significantly from those in the benchmark index. The Fund was attributed the IA Global sector by The IA. The IA Global sector consists of The IA member UK based funds which invest at least 80% of their assets globally in equities. The use of the IA Global sector is purely indicative and should not be used as a benchmark. For further information on The IA and its sectors, visit www.theia.org. ¹Share Class Launch Date 17th April 2024.

PORTFOLIO

Top Ten Holdings

	% ²
Mitsubishi Logistics	5.9
Exor	5.5
D'leteren	5.1
Samsung C&T	4.7
Rohm	4.5
Jardine Matheson	4.5
News Corp A	3.8
Wacom	3.4
Vivendi	3.2
Tokyo Gas	3.2
TOTAL	43.8
No. of Holdings	43


Contributors & Detractors (GBP)³

Largest Contributors	1M Contrib. bps	% ²
Wacom	24	3.4
Rohm	21	4.5
Mitsui OSK Lines	19	3.0
Christian Dior	15	1.3
Tokyo Gas	13	3.2


Largest Detractors	1M Contrib. bps	% ²
D'leteren	-49	5.1
Vivendi	-43	3.2
Jardine Matheson	-36	4.5
Samsung C&T	-34	4.7
Exor	-33	5.5

²Shown as % of Net Asset Value. ³Contributors and detractors from Factset

PORTFOLIO (continued)

Look-through Geographic Exposure⁴

Figures may not total to 100 due to rounding.

Look-through Sector Exposure⁴Figures may not total to 100 due to rounding. ⁴Shown as % of Portfolio

PERFORMANCE SUMMARY

%	Share Class	NAV per share	Month	3 Month	YTD	SI ¹
GBP	A GBP	£107.14	-2.5	5.8	7.2	7.1
	MSCI ACWI	-	0.9	1.5	14.4	47.1
EUR	B EUR	€107.70	-2.3	6.6	9.7	7.7
	MSCI ACWI	-	1.1	2.3	16.9	47.0
GBP	B GBP	£107.79	-2.5	5.9	7.4	7.8
	MSCI ACWI	-	0.9	1.5	14.4	47.1
USD	B USD	\$113.47	-4.6	5.9	6.0	13.5
	MSCI ACWI	-	-1.1	1.6	13.0	57.0
GBP	B1 GBP ⁵	£108.01	-2.5	5.9	7.5	8.0
	MSCI ACWI	-	0.9	1.5	14.4	47.1

Past performance does not predict future returns. All performance is shown, net of fees and including net dividends as at 30/09/2026. Source: Morningstar. Benchmark: MSCI® All Country World Net Total Return Index. The Fund is actively managed with reference to the MSCI® All Country World Net Total Return Index for performance comparison purposes as well as for the purposes of calculating the performance fee. The performance of each share class is stated in the share class relevant currency as specified in the table. The performance of the benchmark has been converted into the currency of the relevant share class for comparison purposes. Returns may increase or decrease as a result of currency fluctuations. The portfolio is unconstrained by the benchmark and holdings may deviate significantly from those in the benchmark index. ¹Share Class Launch Date 17th April 2024. ⁵Performance fee share class - 0.40% management fee + 10% outperformance of benchmark.

MANAGER'S COMMENT

AVI Global Special Situations ("AGSS") NAV decreased by -2.5% in September 2026, compared to a +0.9% rise in our comparator benchmark, the MSCI ACWI (£).

In terms of contributors, it was a relatively lean month: Wacom and Rohm added +24bps and +21bps respectively.

On the other hand, we suffered from a number of larger positions enduring weaker performances leading to more sizeable detractors. Most notably, despite reporting what we thought was a good set of results in early September, D'Ieteren was the largest detractor (-49bps) as the shares declined c. -9% over the course of the month. The company remains one of our largest positions, and we see scope for considerable returns as we move toward a likely IPO of Belron (73% of NAV).

Christian Dior SE:

During the month the Arnault family took further steps to simplify the holding company structure through which they control LVMH. As part of this, the family intends to launch a cash offer for the 2.44% of Christian Dior SE ("CDI") they do not own, at 95% of NAV, with no squeeze out. The NAV will be struck based on LVMH's one-month VWAP in December 2026 and the offer completed in the first quarter of 2027. This saw CDI shares jump +16% in one day and the discount narrow from 21% to 9%.

This was a logical outcome and in line with our expectations – but somewhat galling for it to occur at such an opportunistic time, when LVMH shares trade more than -50% below their all-time high and back at pre-COVID vaccine 2020 levels. All the same we have sold approximately two thirds of our position and retain a toehold that will be monetised in due course.

MANAGER'S COMMENT (continued)

Bio-Rad Labs:

Earlier in 2026 we established a position in Bio-Rad Labs ("Bio-Rad"). The company exhibits many of the traits we look for: 1) attractive growing assets, 2) a discounted valuation, 3) catalysts for change.

The company was founded by husband and wife David and Alice Schwartz in Berkeley, California in 1952 – with the Schwartz family continuing to control the company today (72% of the votes on 32% of the capital). Today the value lies in roughly equal halves between 1) its wholly-owned science tools & equipment business; and 2) a 32% stake in listed Sartorius AG ("SRT") – the German-listed bio-processing equipment company – in which Bio-Rad started building a stake during the early 2000s.

At AVI, we love situations where what you see is not what you get, and where the economics and the accounting diverge. Bio-Rad fits firmly in this camp: the stake in SRT is non-consolidated and as such a simple screen misses significant value. When we started building a position in the spring, the stake in SRT accounted for two thirds of Bio-Rad's market cap. Stripping this (plus net cash & a loan convertible into SRT stock) out, one was paying an implied <\$2bn for the core operating business that should produce c.\$430m of EBITDA this year. Peers – both listed comps and M&A transactions – are valued at many times this derisory multiple.

Taking the two halves in turn, SRT began in the 1870s as a maker of precision laboratory balances and moved into biopharma through acquisitions in 2000 and 2007. The company is controlled (55% of the ordinary shares) by the Estate of Horst Sartorius, which was set up in 1998 upon his death to maintain control of the company. The Estate is divided between his three daughters and managed by an executor until it dissolves in 2028.

Looking at SRT the vast bulk of profit and value comes from Bio Process Solutions ("BPS"), which supplies the equipment and consumables used to manufacture biologic drugs (medicines grown in living cells rather than synthesised). The (brief!) history of the pharmaceutical industry over the last 50 years is one of biology usurping chemistry and a move from vertical integration to specialisation. In this process, significant value now accrues to the companies – such as SRT – that provide the infrastructure for production, as (biologic) process has been inseparable from the product – from both a scientific and regulatory perspective. This is a highly attractive business with long-term compounding potential: robust underlying market growth underpinned by biologics; teens returns on capital. As one of the few scaled, listed bioprocessing specialists globally, SRT is a scarce and highly desirable asset.

That said, it has not been a smooth ride. COVID led to a historic pull-forward in demand which took far longer than anticipated to unwind as the book-to-bill ratio shunted down. The shares fell close to -70% peak to trough which was enough to see the CEO and CFO replaced. With that said, over the last year the corner has been turned, and we are now firmly in recovery. At the recent Capital Markets Day, management set out targets for mid-term growth of 8-11% underpinned by BPS growth of 9-12% and margins expected to expand between 50-75bps p.a.

The market is well aware of these highly attractive characteristics and has historically capitalised the business at a premium multiple. As things stand the company trades at c.20x 2026 EV/EBITDA. Valuation risk is certainly something we considered but in the round trip of the investment case we believe it to be manageable and are encouraged by the continued high near-

term multiples the sector achieves in M&A transactions.

Bio-Rad's own business splits 40:60 between Life Science and Clinical Diagnostics. Life Science supplies instruments and consumables to separate, purify and quantify biological materials such as cells, proteins and DNA, selling to academic and government labs and, increasingly, biopharma. It is the familiar razor blade model: an installed base of instruments generating a recurring stream of consumables. Clinical Diagnostics sells test systems and kits to hospital and reference labs, covering more than 300 tests including diabetes A1C blood tests, packaged as an instrument, reagent and software bundle which becomes quite sticky once a lab standardises on it. It is a less glamorous market, growing at a GDP-ish in line with patient volumes. In total the group sells >12k products, no customer accounts for more than 2% of sales, and >70% of revenues are recurring in nature.

That said, Bio-Rad's own business has been undermanaged – leading to subpar topline growth and a bloated cost structure. SG&A has grown in line with revenue (both 3.1x since 2001) and now absorbs 32% of sales. Gross margins are in line with peers in the 50s, yet operating margins are c.12% against peers in the high teens and 20s. That is nearly a quarter of a century without any operating leverage. The same story shows up in the products. Bio-Rad pioneered digital PCR (the more granular cousin of the PCR test familiar from COVID) and has c.75% of the market, but former employees describe weak go-to-market execution and a lack of commercial planning, which has let competitor Qiagen take c.20% share. Investors are also frustrated with capital allocation, particularly around the SRT stake, where the value is masked to the unobservant and the more observant have (rightly) queried if value will ever be harvested.

Taken together these factors have resulted in the market applying a heavy discount to Bio-Rad's sum-of-the-parts and implicitly valuing the stub at next to nothing. We believe a number of factors are now aligning that should prompt a reassessment.

Having followed the company for a number of years we have observed a shift in tone – both on the core operations and the stake in SRT. Earlier in 2026 the company announced a new restructuring program, and in recent conversations with the (relatively) new CFO we are encouraged by the shift in tone and dynamism. Notably when it comes to SRT, Bio-Rad described it as a "monetizable asset" for the first time in 2024. Elliott Management – the activist hedge fund – recently announced a position in the company and we suspect this is sharpening the minds of the family even if they are somewhat protected by the dual-voting stock. The other pertinent catalyst relates to SRT and dissolution of the Sartorius family Trust. As we look toward 2028, we believe this will effectively put SRT in-play as a highly desirable asset in an industry that has trended toward consolidation.

As we see it there are three principal risks to the investment case. Arguably the largest is that Bio-Rad uses the SRT shares, or the proceeds of a sale, to do something silly, and with the family in control and succession unclear, minority shareholders have little recourse. Beyond that, continued underperformance of the core Bio-Rad business both in terms of topline growth and cost improvement could impede a re-rating in the stub; and SRT remains a high-multiple business that carries the expectations that come with one.

Returns so far have been strong (with an ROI of +21% in a handful of months) as the Stub has started to re-rate. We believe this has further to run and see the ingredients in place for attractive returns as we look out over the coming years.



RISK & REWARD

Fund Attributes

- High-conviction concentrated portfolio
- Actively managed with emphasis on Sum of the Parts (SOTP) valuations and exploiting discounts
- Global portfolio diversified across a range of sectors and geographies

Fund Risks

As a focused equity portfolio of between 35 and 45 investments, the Fund can involve higher risk and higher volatility. The value of an investment can fall as well as rise as a result of market and currency movement; you may not get back the amount originally invested. You should therefore regard your investment as long term. Details on the risk factors are included in the Fund's prospectus, available on our website.

ESG

ESG Integration

ESG is integrated into each stage of our investment process. AVI has eschewed a box-ticking approach to ESG and developed a proprietary ESG monitoring system.

Engagement is central to our strategy. Our ESG monitoring system helps to highlight areas where we can actively engage with portfolio companies to build resilience to sustainability risks, promote responsible attitudes, and enhance sustainable corporate value.

For more information, AVI's ESG Report can be accessed on its website [here](#)

Article 6

This Fund has an Article 6 classification within the meaning of the Sustainable Finance Disclosure Regulation (SFDR). Engagement is central to delivering long term returns, and we integrate environmental, social and governance (ESG) factors into our risk management on an ongoing basis. As part of our engagement process, we monitor the climate-related risks of our portfolio companies within a bespoke system developed for AVI. However, the Fund does not have a sustainability objective.

FUND DETAILS

AVI Global Special Situations Fund

Fund Launch Date	17 th April 2024
Base Currency	USD
Net Asset Value	USD48m / GBP36.1m
IA Sector	Global
Fund Structure	UCITS
Fund Domicile	Ireland
Investment Manager	Asset Value Investors
Manager	Gateway Fund Services
Administrator/Transfer Agent	Société Générale
Dealing	Daily
Subscription Deadline	1 Business Day prior by 12PM
Dealing Information*	info@assetvalueinvestors.com

*Also available on all major platforms.

Share Classes

Share Class	OCF ⁶ (%)	ISIN	Ticker
A (GBP)	1.0	IE000JIDJD84	AVIGLSA ID
B (EUR)	0.8	IE0005EAPTK6	AVIGLSB ID
B (GBP)	0.8	IE0008Q72UI9	AVIGLBG ID
B (USD)	0.8	IE000DG5O9L7	AVIGLBU ID
B1 (GBP) ⁵	0.65	IE000U617EI1	AVIGLB1 ID

Benchmark: MSCI® All Country World Net Total Return Index

⁵Performance fee share class - 0.40% management fee + 10% outperformance of benchmark

⁶Ongoing Charges Figure - figure shown reflects maximum charge. The actual OCF may be lower and may fluctuate over time. See KIID for details

Investment Manager – Joe Bauernfreund

AVI Ltd. +44 20 7659 4800 info@assetvalueinvestors.com

The share price can be found in [AGSS - Asset Value Investors](#)

Further information may be found on www.assetvalueinvestors.com



IMPORTANT INFORMATION

All figures are as at the period under review unless otherwise stated. All sources Asset Value Investors Ltd ("AVI") unless otherwise stated. AVI is authorised and regulated by the Financial Conduct Authority of the United Kingdom (the "FCA"), reference number 119270 and is a registered investment adviser with the Securities and Exchange Commission of the United States. While AVI is registered with the SEC as an investment adviser, it does not comply with the Advisers Act with regard to its non-U.S. clients. This document is provided for information purposes only and does not constitute an offer to buy or sell shares in AVI Global Special Situations (the "Fund"). The contents of this message are not intended to constitute, and should not be construed as investment advice. This material is intended for professional clients and eligible counterparties only. It is not intended for retail clients. The distribution of this material may be restricted by law and persons into whose possession it comes are required to inform themselves of and comply with any such restrictions. Potential investors in the Fund should seek their own independent financial advice. AVI neither provides investment advice to, nor receives and transmits orders from, investors in the Fund. Past performance is not an indicator of future results, and you may not get back the original amount invested. This is a marketing communication. Please refer to the Prospectus and the KIID, available at www.assetvalueinvestors.com/agss, before making any final investment decision. Gateway Fund Services Limited is authorised and supervised by the Central Bank of Ireland under reference number C18307. A summary of investor rights associated with an investment in the Fund shall be available in English from www.gatewayfunds.com. MSCI® is a registered trademark of MSCI Inc. and/or its affiliates. The use of MSCI indices or data does not imply sponsorship, endorsement, or affiliation with MSCI.